Long Before Deeptech Became Fashionable And Biotech Became A Venture-Capital Darling, One Institution Was Quietly Building The Foundations Of India's Biotechnology Startup Revolution. That Institution Was BIRAC.
When people talk about India's startup success story, the conversation usually revolves around fintech, SaaS, e-commerce or artificial intelligence.
These sectors have produced unicorns, attracted billions of dollars in investment and generated global headlines. Biotechnology, by comparison, has often remained outside the spotlight. The sector moves more slowly, requires deeper scientific expertise and demands significantly larger investments before products reach the market. Unlike software startups that can launch products within months, biotech companies often spend years navigating research, clinical validation and regulatory approvals before generating meaningful revenue.
Yet biotechnology is becoming one of India's most important innovation frontiers.
From drug discovery and precision medicine to agricultural biotechnology and industrial bio-manufacturing, startups are increasingly tackling complex scientific challenges with the potential to create global impact. The ecosystem now includes thousands of ventures working across healthcare, diagnostics, therapeutics, synthetic biology and sustainable technologies. What makes this growth remarkable is that it did not emerge organically. It required infrastructure, funding, mentorship and long-term policy support long before private investors were willing to participate at scale.
That is where the Biotechnology Industry Research Assistance Council, better known as BIRAC, enters the story.
Established by the Department of Biotechnology, BIRAC was created with a mission that extended beyond simply funding research. It sought to bridge one of India's most persistent innovation gaps: the distance between scientific discovery and commercial success. Over the years, the organization has evolved into one of the most influential institutions in India's startup ecosystem, helping transform academic ideas into companies, supporting entrepreneurs through critical early stages and creating infrastructure capable of nurturing high-risk innovation.
The result is an impact that reaches far beyond individual startups.
BIRAC has become one of the key architects of India's modern bioeconomy, helping create an ecosystem that is increasingly attracting entrepreneurs, investors and global attention. As of 2025, India's bioeconomy had reached approximately $195.3 billion and was supported by more than 11,800 biotech startups, reflecting the scale of growth occurring across the sector.
Building An Ecosystem Before One Existed
One of BIRAC's most important contributions was recognizing a challenge that many policymakers overlooked.
Biotech startups cannot be built using the same playbook as software companies. Entrepreneurs in life sciences require laboratories, specialized equipment, regulatory expertise and access to scientific talent. The costs are higher, the timelines are longer and the risks are significantly greater. Without dedicated support systems, many promising ideas never move beyond the research stage.
BIRAC's response was to focus on ecosystem creation rather than isolated funding.
Instead of merely providing grants, the organization invested in incubation infrastructure, mentorship networks and industry-academia collaboration. Through initiatives such as BioNEST, BIRAC helped establish incubators capable of supporting biotech entrepreneurs with laboratory access, technical guidance and business-development resources. These facilities became critical launchpads for startups attempting to navigate the difficult journey from research to commercialization.
The strategy addressed one of the most difficult challenges facing early-stage biotech ventures.
Scientific founders often possess strong technical capabilities but limited exposure to fundraising, intellectual-property management, regulatory pathways and commercialization strategies. Incubation programs helped bridge those gaps by connecting entrepreneurs with mentors and industry experts capable of accelerating development. Over time, these support structures created a pipeline of startups capable of attracting external investment and competing globally.
Today, the scale of this infrastructure is substantial.
Government data indicates that DBT-BIRAC has helped establish a nationwide network of bio-incubators spanning multiple states and union territories, creating one of the largest publicly supported biotech innovation networks in the country.
Solving The Funding Problem
Access to capital has historically been one of the biggest barriers facing biotech entrepreneurs.
Unlike many technology startups, biotech ventures often require significant investment before reaching proof of concept. Traditional investors are frequently hesitant to fund such projects because timelines are uncertain and scientific risk remains high. This creates a financing gap commonly referred to as the "valley of death" — the period between early research and commercial viability.
BIRAC developed multiple programs specifically designed to address this challenge.
Among the most influential is the Biotechnology Ignition Grant (BIG), which provides early-stage funding to help entrepreneurs transform innovative ideas into proof-of-concept projects. The program offers support for researchers, startups and academic spin-offs attempting to validate technologies with commercial potential. Over the years, BIG has become one of the most recognized funding mechanisms within India's biotech ecosystem.
The support extends beyond the earliest stages.
Programs such as the SEED Fund help startups move from proof of concept toward investment readiness by providing bridge financing and support during critical growth phases. These interventions reduce risk for future investors while improving the likelihood that promising technologies survive long enough to reach commercialization.
The impact has been significant.
BIRAC's funding mechanisms have helped create a pipeline of ventures operating across healthcare, agriculture, industrial biotechnology and environmental sustainability. By absorbing risks that private investors were often unwilling to take, the organization has enabled innovation that might otherwise never have reached the market.
Creating India's Deeptech Biotech Culture
Perhaps BIRAC's greatest contribution has been cultural.
A decade ago, biotech entrepreneurship in India was relatively uncommon. Many scientists pursued academic careers because commercial pathways appeared difficult and underdeveloped. Building a startup around scientific research often seemed impractical due to funding constraints and limited ecosystem support.
BIRAC helped change that perception.
By providing grants, incubation support and commercialization pathways, it demonstrated that scientific entrepreneurship could become a viable career choice. Researchers increasingly viewed startups as legitimate vehicles for translating discoveries into real-world solutions. This shift encouraged more scientists, engineers and healthcare innovators to pursue entrepreneurial ambitions.
The transformation is visible in the numbers.
India's biotech startup ecosystem has grown dramatically over the past decade, with thousands of ventures emerging across diverse segments of the life-sciences sector. Much of this expansion has occurred alongside the growth of BIRAC-supported programs and infrastructure.
Importantly, the impact extends beyond startup creation.
The ecosystem has generated jobs, attracted private investment and strengthened India's position within the global biotechnology landscape. It has also encouraged stronger collaboration between academia, industry and government institutions.
The Next Phase Of Growth
BIRAC's role continues evolving as the biotech ecosystem matures.
The focus is increasingly expanding toward advanced areas such as cell and gene therapy, synthetic biology, biomanufacturing and precision healthcare. New partnerships, translational research initiatives and commercialization programs aim to help Indian startups compete within some of the world's most sophisticated biotechnology markets.
This transition reflects broader changes within India's innovation economy.
The country is no longer focused solely on producing affordable solutions. It is increasingly attempting to create original intellectual property, advanced technologies and globally competitive scientific enterprises. Biotechnology sits at the center of that ambition because it combines economic opportunity with societal impact.
Investors are paying attention.
Deeptech and life-sciences startups are attracting growing interest as India's bioeconomy continues expanding. The infrastructure created over the past decade provides a stronger foundation for future growth than existed previously, making the sector increasingly attractive for long-term capital.
The ecosystem remains young relative to global leaders, but the trajectory is becoming increasingly difficult to ignore.
The Bigger Story
Viewed narrowly, BIRAC is a funding and support organization.
Viewed more broadly, it is one of the most important institutions behind India's biotechnology transformation. Its influence extends beyond grants and incubators into the very structure of the country's innovation ecosystem. By supporting entrepreneurs, reducing scientific risk and creating commercialization pathways, BIRAC has helped turn biotechnology from a niche sector into a meaningful contributor to economic growth.
The impact can now be measured not only in startups but also in the broader bioeconomy.India's biotechnology sector has expanded rapidly, creating opportunities across healthcare, agriculture, sustainability and industrial innovation. Many of the companies driving this growth emerged from an ecosystem that BIRAC helped build.Because successful startup ecosystems are rarely created by capital alone.
They are built through institutions willing to invest in innovation long before the rest of the market recognizes its value.And in India's biotech story, few institutions have played a bigger role than BIRAC.
